Zura Bio (NASDAQ:ZURA) Given Neutral Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Zura Bio (NASDAQ:ZURA - Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 target price on the stock.

A number of other brokerages have also commented on ZURA. Piper Sandler reiterated an "overweight" rating and set a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zura Bio in a report on Friday.

Zura Bio Stock Performance

Shares of NASDAQ ZURA traded down $0.09 during midday trading on Monday, reaching $4.83. 187,946 shares of the company were exchanged, compared to its average volume of 325,173. The stock's 50-day moving average price is $3.92 and its 200-day moving average price is $3.96. Zura Bio has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). On average, equities analysts expect that Zura Bio will post -0.47 EPS for the current fiscal year.

Insider Activity at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of the business's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zura Bio

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC acquired a new position in Zura Bio in the second quarter valued at $43,000. Renaissance Technologies LLC lifted its holdings in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after buying an additional 5,900 shares during the period. SG Americas Securities LLC acquired a new position in Zura Bio in the third quarter valued at $62,000. Forefront Analytics LLC lifted its holdings in Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock valued at $145,000 after buying an additional 7,531 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock valued at $165,000 after purchasing an additional 6,412 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.